Changing therapeutic paradigms in CMV retinitis in AIDS

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 7, 2000, Pages 1343-1352

  Piper, Heidi ^a   Ciulla, Thomas A ^a   Danis, Ronald P ^a   Pratt, Linda M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral; Cidofovir; Cmv retinitis; Eye; Fomivirsen; Foscarnet; Ganciclovir

Indexed keywords

ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; HUMAN; RETINITIS; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 0034572937     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.7.1343     Document Type: Article

References (70)

1. LASK1N OL: Acyclovir. Pharmacology and clinical experience. Arch. Intern. Meet. (1984) 144:1241-12-46.
2. TEICH SA, CHEUNG TW, FRIEDMAN AH: Systemic antiviral drugs used in ophthalmology. Sitrv. Optyhalmol. (1992) 37:19-53.
3. LITTLER E, ZEUTHEN J, MCBRIDE AA et a!.: Identification of an Epstein-Barr virus-coded thymidine kinase. EMBOJ. (1986) 5:1959-1966.
4. MILLER WH, MILLER RL: Phosphorylation of acyclovir (acycloguanosine) monophosphateby GMP kinase.J. Biol. Chem. (1980) 255:7204-7207.
5. FURMAN PA, ST. CLAIR MH, FYFE JA et al.: Inhibition of herpes simplex virus-induced DNA polymcrase activity and viral DNA replication by 9-t2-hydroxyethoxymethyl)guanine and its triphosphate.J. Virol. (1979) 32:72-77.
6. DERSE D, CHENG YC, FURMAN PA, ST. CLAIR MH, ELION GB: Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J. Biol. Chem. (1981) 256:11447-11451.
7. CRUMPACKER CS, SCHNIPPER LE, MARLOWE SI et al.-. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. Ar. Engl.J. Med. (1982) 306:343-346.
8. BURNS WH, SARAL R, SANTOS GW et ah: Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet (1982) 1:421-423.
9. ERLICH KS, MILLS J, CHATIS P et al: Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl.J. Med. (1989) 320:293-296.
10. COLLINS P: Viral sensitivity following the introduction of acyclovir. Am.J. Med. (1988) 85:129-134.
11. COLLINS P, LARDER BA, OLIVER NM et ah. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir.J. Gen. Virol. (1989) 70:375-382.
12. JACOBSON MA, DREW WL, FEINBERG J et ah. Foscarnet therapy for ganclclovir-resistant cytomegalovirus retinitis in patients with AIDS. / Infect. Dis. (1991) 163:1348-1351.
13. FIELD AK, BIRON KK: 'The end of innocence' revisited: resistance of herpesviruses to antiviral drugs. Clin. Micwbiol. Rev. (1994) 7:1-13.
14. BIRON KK, FYFE JA, STANAT SC et al.: A human cytomegalovirus mutant resistant to the nucleoside analog 9-((2-hydroxy-l-(hydroxymethyl)ethoxy) methyl)guanine (BW B759U) induces reduced levels of BWB759U triphosphate. Proc. Natl. Acad. Sei. USA (1986) 83:8769-8773-
15. LURAIN NS, SPAFFORD LE, THOMPSON KD: Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. (1994) 68:4427-4431.
16. LURAIN NS, THOMPSON KD, HOLMES EV, READ GS: Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents./ Virol. (1992) 66:7146-7152.
17. BROWN F, BANKEN L, SAYWELL K, ARUM I: Pharmacokinetics of valganclclovir and ganciclovir following multiple oral dosages of valganciclovir In HIV-and CMV-seropositive volunteers. Clin. Phannacokln. (1999) 37:167-176.
18. JUNG D, DORR A: single-dose pharmacokinetics of valganciclovir in HIV and CMV seropositive subjects./ Cltn. Pharmacol. (1999) 39:800-804.
19. HATTON MP, DUKER JS, REICHEL E, MORLEY MG, PULIAFITO CA: Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant. Retina (1998) 18:50-55.
20. KUPPERMANN BD, QUICENO JI, FLORES-AGUILAR M et ah: Intravitreal ganciclovir concentration after intravenous administration in AIDS patients -with cytomegalovirus retinitis: implications for therapy.J. Infect. Dis. (1993) 168:1506-1509.
21. MARTIN DF, PARKS DJ, MELLOW SD et al: Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant A randomized controlled clinical trial. Arch. Ophtbalmol. (1994) 112:1531-1539.
22. ROTH DB, FEUER WJ, BLENKE AJ, DAVIS JL: Treatment of recurrent cytomegalovirus retinitis with the ganciclovir implant. Am. J. Ophthalmol. (1999) 127:276-282.
23. MUSCH DC, MARTIN DF, GORDON JF, DAVIS MD, KUPPERMANN BD: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant The Ganciclovir Implant Study Group. N. Eng!. J. A fed. (1997) 337:83-90.
24. MARTIN DF, KUPPERMANN BD, WOLITZ RA et al.: Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. Ar. Eugl.J. Mcd. (1999) 340:1003-1070.
25. SAFRIN S, ASSAYKEEN T, FOLANSBEE S: Foscarnet therapy in five patients with acyclovir resistant varicella zoster virus infection. Ann. Intern. Mcd. (1990) 115:19.
26. Combination foscamet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch. Ophtbalmol. (1996) 114:23-33.
27. HOLLAND GN, LEVINSON RD, JACOBSON MA: Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team. Am. J. Ophthalmol. (1995) 119:576-586.
28. PERRY CM, BALFOUR JA: Fomivirsen. Drugs (1999) 57:375-380; Discussion 381.
29. AMIN HI, AI E, MCDONALD HR, JOHNSON RN: Retinal toxic effects associated with intravitrcal fomivirsen. rch. Ophthalmol. (2000) 118:426-427.
30. WHITCUP SM: Cytomegalovirus retinitis in the era of highly active antlretroviral therapy (clinical conference). JAMA (2000) 283:653-657.
31. AMBATI J, WYNNE KB, ANGERAME MC, ROBINSON MR: Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br. J. Ophtbalmol. (1999) 83:1153-1158.
32. DAVIS JL, TASKINTUNA I, FREEMAN WR ct al.: Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch. Ophtbalmol. (1997) 115:733-737.
33. BAGNIS C, 1ZZDINE H, DERAY G: Renal tolerance of cidofovir. Therapie (1999) 54:689-691.
34. HO ES, LIN DC, MENDEL DB, CIHLAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter I.J. Am. Soc. Kephrol. (2000) 11:383-393.
35. CUNDY KG: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. din. Pharmacokinet. (1999) 36:127-143.
36. LACY SA, HITCHCOCK MJ, LEE VA, TELLIER P, CUNDY KC: Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in Cynontolgus monkeys. Toxicol. Sei. (1998) 44:97-106.
37. PLOSKER GL, NOBLE S: Cidofovirj a review of its use in cytomegalovirus retinitis in patients with AIDS. Dmgs (1999) 58:325-345.
38. CARPENTER CC, FISCHL MA, HAMMER SM et ah. Antiretroviral therapy for HTV infection in 1998: updated recommendations of the International AIDS Society USA Panel JAMA (1998) 280:78-86.
39. VRABEC TR, BALDASSANO VF, WHITCUP SM: Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology (1998) 105:1259-1264.
40. TORRIANI FJ, FREEMAN WR, MACDONALD JC et al.: CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. ,1/05(2000) 14:173-180.
41. TURAL C, ROMEU J, SIRERA G et al.: Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. (1998) 177:1080-1083.
42. JACOBSON MA, STANLEY H, HOLTZER C, MARGOLIS TP, CUNNINGHAM ET: Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy, din. Infect. Dis. (2000) 30: 231-233.
43. MACDONALD JC, KARAVELLAS MP, TORRIANI FJ et al.: Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology (2000) 107: 877-881; Discussion 881-883.
44. HOLLAND GN: New issues in the management of patients with AIDS-related cytomegalovirus retinitis. Arch. Ophthalmol (2000) 118:704-706.
45. SONG MK, KARAVELLAS MP, MACDONALD JC, PLUMMER DJ, FREEMAN VR: Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina (2000) 20:151-155.
46. WALMSLEY S, TSENG A: Comparative tolerability of therapies for cytomegalovirus retinitis. DnigSaf.(l999) 21:203-224.
47. BALDANTI F, SILINI E, SARASINI A et at.: A threenucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. (1995) 69:796-800.
48. ERICE A, GIL-RODA C, FEREZ JL et at.-. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. (1997) 175:1087-1092.
49. SMITH IL, SHINKAI M, FREEMAN VR, SPECTOR SA: Polyradiculopathy associated -with ganciclovirresistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates.J. Infect. Dis. (1996) 173:1481-1484.
50. BOIV1N G, CHOU S, QUIRK MR, ERIGE A, JORDAN MC: Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease.J. Infect. Dis. (1996) 173:523-528.
51. CHOU S, ERIGE A, JORDAN MC e/flJ.: Analysis of the UL97 phosphotransfcrase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. (1995) 171:576-583.
52. DREW VL, MINER RC, BUSCH DF et al.: Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. (1991) 163:716-719.
53. JABS DA, ENGER C, DUNN JP, FORMAN M: Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.J. Infect. Dis. (1998) 177:770-773.
54. GILBERT C, HANDHELD J, TOMA E étal.: Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS (1998) 12:125-129.
55. CHOU S, GUENTZEL S, MICHELS KR, MINER RC, DREW WL: Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates.J. Infect. Dis. (1995) 172:239-242.
56. SPECTOR SA, HIRATA KK, NEWMAN TR: Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J. Infect. Dis. (1984) 150:953-956.
57. COLLIER AC, CHANDLER SH, HANDSFIELD HH, COREY L, MCDOUGALL JK: Identification of multiple strains of cytofliegalovirus in homosexual men. J. Infect. Dis. (19S9) 159:123-126.
58. PEEK R, VERBRAAK F, BRUINENBERG M et al.: Cytomegalovirus glycoprotcin B genotyping in ocular fluids and blood of AIDS patients with cytomegalovirus retinitis. Invest. Opbtbalmol. Vis. Set. (1998) 39:1183-1187.
59. SMITH IL, TASKINTUNA I, RAHHAL FM et al.: Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. (1998) 116:178-185-
60. RASMUSSEN L, HONG C, ZIPETO D et a!.: Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. / Infect. Dis. (1997) 175:179-184.
61. SPECTORSA, WONG R, HSIA K, PILCHERM, STEMPIEN MJ: Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J. Clin, Invest. (1998) 101:497-502.
62. MITCHELL SM, FOX JD, TEDDER RS, GAZZARD BG, LIGHTMAN S: Vitreous fluid sampling and viral genome detection for the diagnosis of viral retinitis in patients with AIDS.J. Mud. Vim!. (1994) 43:336-3-40.
63. GARWEG J, FENNER T, BOHNKE M, SCHWITZ H: An improved technique for the diagnosis of viral retinitis from samples of aqueous humor and vitreous. Graefes Arch. Clin. Exp. Ophthalmol. (1993) 231:508-513.
64. DE BOER JH, VERHAGEN C, BRUINENBERG M et al.-. Serologie and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am.J. Ophthalmol. (1996) 121: 650-658.
65. DOORNENBAL P, SEERP BAARSMA G, QUINT VG et al.: Diagnostic assays in cytomegalovirus retinitis: detection of herpes virus by simultaneous application of the polymerase chain reaction and local antibody analysis on ocular fluid. Br. J. Opbthalmol. (1996) 80: 235-240.
66. MCCANN, JD, MARGOLIS, TP, WONG, MG et al.: A sensitive and specific polymerase chain reactionbased assay for the diagnosis of cytomegalovirus retinitis. Am.J. Ophthalmol. (1995) 120:219-226.
67. SILVERSTEIN BE, CONRAD D, MARGOLIS TP, WONG IG: Cytomegalovirus-associated acute retinal necrosis syndrome. Am.J. Ophthalmol. (1997) 123:257-258.
68. NISHIM, HANASHIRO R, MORIS étal.: Polymerase chain reaction for the detection of the varicella-zoster genome in ocular samples from patients with acute retinal necrosis. Am.J. Ophthalmol. (1992) 114:603-609.
69. FENNER TE, GARWEG J, HUFERT FT, BOEHNKE M, SCHMITZ H: Diagnosis of human cytomegalovirusinduced retinitis in human immunodeficiency virus Type 1-infected subjects by using the polymerase chain reaction./ Clin. Microbiol. (199D 29:2621-2622.
70. LIU W, KUPPERMANN BD, MARTIN DF, WOLITZ RA, MARGOLIS TP: Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. / Infect. Dis. (1998) 177:1176-1181.